FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures

Abstract

FOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple myeloma but has not been studied in DLBCL, where a poor prognosis activated B-cell (ABC)-like subtype display partially… (More)
DOI: 10.18632/oncotarget.9507

Topics

10 Figures and Tables

Statistics

05020162017
Citations per Year

Citation Velocity: 21

Averaging 21 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.

Slides referencing similar topics